Protocol Ledger

NCT06935370 · Phase III · RECRUITING

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

Interventional Phase III clinical trial protocol NCT06935370 sponsored by Boehringer Ingelheim in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-20 Enrollment: 4,200 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06935370
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)4,200 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06935370
Protocol FieldVerified Registry Value
NCT IdentifierNCT06935370
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment4,200 participants (ESTIMATED)
Registered Start Date2025-05-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06935370
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI